Laboratory Director Sample Clauses

Laboratory Director. With accreditation of Environmental Laboratory Accreditation Program (ELAP), an employee serving as the Laboratory Director shall receive 7% above base pay. The assignment shall be made available on an equal basis to all eligible employees and rotated every two (2) years concurrent with laboratory certification renewal from the State. The following job classifications shall be eligible for this differential pay: Water Treatment Plant Operator Classes Water Treatment Plant Operations Supervisor
AutoNDA by SimpleDocs
Laboratory Director. The Practice shall appoint one of its Practice Providers who is a licensed pathologist to serve as the laboratory director (the “Laboratory Director”) of the laboratory operated by , an affiliate of Manager. The Laboratory Director shall maintain the Practice’s standards and professional ethics and those of the medical profession. The duties of the Laboratory Director shall include, but shall not be limited to, monitoring testing results, evaluating quality controls and implementing corrective actions in conjunction therewith; reviewing procedure manuals, including amendments thereto; reviewing policies regarding specimen repeat and slide review ranges; assisting in the provision of continuing education for technologists; acting as a liaison between Manager and physicians and other laboratories; and performing such other duties as are required of a laboratory director under the Clinical Laboratory Improvements Act and other applicable state laws.
Laboratory Director. The Laboratory Director will be identified in the Site-specific 23 QAPP Addenda. The Laboratory Director is responsible for the following:
Laboratory Director. The Laboratory Director is a technical advisor and is responsible for summarizing and reporting overall unit performance. Responsibilities include: ■ Provide technical, operational, and administrative leadership; ■ Allocation and management of personnel and equipment resources; ■ Quality performance of the facility; ■ Certification and accreditation activities; and ■ Compliance with audits and corrective actions.
Laboratory Director. Shall meet the Secretary of the Interior’s historic preservation qualification standards for Archaeologist, including a graduate degree in Anthropology with a specialization in Archaeology or a graduate degree in Archaeology or related field as defined in FR Vol. 62 (119): 33707-337231 for archaeologist; OR meet the Secretary of Interior’s historic preservation qualification standards for Conservator, including a graduate degree in Conservation or graduate degree in a closely related field of study with a certificate in Conservation; Plus five (5) years full-time professional experience applying the theories, methods, and practices of Pacific (Micronesia and Polynesia) or Asian archaeology that enables professional judgments to be made about the identification, evaluation, documentation, or treatment of prehistoric or historic archaeological materials in the Pacific or Asia, as appropriate for the assignment, and which includes professional supervisory experience working with various midden, artifact, and other cultural materials from the Pacific and/or Asia. This person(s) shall have products and activities that demonstrate the successful ability to implement research designs, conduct and supervise laboratory analyses, make strategic decision in the laboratory, and communicate orally and in writing as evidenced by their completed technical reports and/or publications. This person(s) shall work closely with the Principal Investigator and Project Director, write all technical laboratory reports, oversee and direct procurement of all analyses, materials processing, cataloging and conservation, data production, and data base management as necessary.
Laboratory Director. Consultant shall provide either (i) two laboratory directors, one of which is licensed to practice medicine without restriction in the State of California, and the other of which holds a certificate of qualification in generic testing/molecular oncology in the State of New York, or (ii) one laboratory director who meets both criteria set forth in the previous clause (i) (such laboratory director(s), the “Laboratory Director(s)”) each of whom will be licensed and qualified, and shall remain in good standing with, all applicable federal and state laws, including, without limit, the federal Clinical Laboratory Improvement Amendments and its implementing regulations (“CLIA”); the State of California’s Business and Professions Code and/or the applicable state laboratory laws and rules in the state of New York, as applicable; the Laboratory’s accrediting bodies (if applicable) (collectively, the “Laboratory Rules”). The Laboratory Directors shall be responsible for performing, or arranging for or delegating as permitted, all the duties and responsibilities required under the Laboratory Rules (the “Laboratory Director Services”). Each Laboratory Director will assist the Laboratory in maintaining compliance with all applicable federal and state laws, rules, regulations, standards and ordinances, and judicial and administrative interpretations thereof, all criteria and standards of applicable accreditation agencies of Laboratory, and all other policies and procedures duly established by Company and the Laboratory, including, without limit, the services and activities set forth in Exhibit A attached hereto. At all times during the term of this Agreement, Laboratory Director will meet all of the qualifications (“Laboratory Director Qualifications”) as follows:

Related to Laboratory Director

  • Medical Director The Contractor shall employ the services of a Medical Director who is a licensed Indiana Health Care Provider (IHCP) provider board certified in family medicine or internal medicine. If the Medical Director is not board certified in family medicine, they shall be supported by a clinical team with experience in pediatrics, behavioral health, adult medicine and obstetrics/gynecology. The Medical Director shall be dedicated full-time to the Contractor’s Indiana Medicaid product lines. The Medical Director shall oversee the development and implementation of the Contractor’s disease management, case management and care management programs; oversee the development of the Contractor’s clinical practice guidelines; review any potential quality of care problems; oversee the Contractor’s clinical management program and programs that address special needs populations; oversee health screenings; serve as the Contractor’s medical professional interface with the Contractor’s primary medical providers (PMPs) and specialty providers; and direct the Quality Management and Utilization Management programs, including, but not limited to, monitoring, corrective actions and other quality management, utilization management or program integrity activities. The Medical Director, in close coordination with other key staff, is responsible for ensuring that the medical management and quality management components of the Contractor’s operations are in compliance with the terms of the Contract. The Medical Director shall work closely with the Pharmacy Director to ensure compliance with pharmacy-related responsibilities set forth in Section 3.4. The Medical Director shall attend all OMPP quality meetings, including the Quality Strategy Committee meetings. If the Medical Director is unable to attend an OMPP quality meeting, the Medical Director shall designate a representative to take his or her place. Notwithstanding the Medical Director ‘s sending of a representative, the Medical Director shall be responsible for knowing and taking appropriate action on all agenda and action items from all OMPP quality meetings.

  • Joint Manufacturing Committee In accordance with Section 2.5(c)(iv), the Parties shall promptly establish and convene a joint Manufacturing Committee (the “JMC”) for the overall coordination and oversight of the Manufacturing of clinical and commercial supplies of the Product under this Agreement as provided in the Manufacturing Plan (including the Manufacture of API, Drug Product and Finished Product). The JMC shall consist of representatives of each Party, and shall operate by procedures, as set forth in Section 2.5. The role of the JMC shall be:

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Joint Patent Committee (a) The Parties will establish a “

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Chair The Chair of the Union/Management Committee shall alternate between an Employer representative and a representative of the Union.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Committee Composition The Redeployment Committee shall be comprised of equal numbers of representatives of the Hospital and of the Union. The number of representatives will be determined locally. Where for the purposes of HTAP (the Ontario Hospital Training and Adjustment Panel) there is another hospital-wide staffing and redeployment committee created or in existence, Union members of the Redeployment Committee shall serve on any such hospital-wide staffing committee established with the same or similar terms of reference, and the number of Union members on such committee will be proportionate to the number of its bargaining unit members at the particular Hospital in relation to other staff groups. Meetings of the Redeployment Committee shall be held during normal working hours. Time spent attending such meetings shall be deemed to be work time for which the representative(s) shall be paid by the Hospital at his or her regular or premium rate as may be applicable. Each party shall appoint a co-chair for the Redeployment Committee. Co-chairs shall chair alternative meetings of the Committee and will be jointly responsible for establishing the agenda of the Committee meetings, preparing minutes and writing such correspondence as the Committee may direct.

Time is Money Join Law Insider Premium to draft better contracts faster.